Hypertrophic cardiomyopathy: Evaluation and treatment of patients at high risk for sudden death

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 2 II, 1997, Pages 478-501

  Fananapazir, Lameh ^a,b   Mcareavey, Dorothea ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

hypertrophic cardiomyopathy; sudden death; systolic and diastolic dysfunction

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROCAINAMIDE; QUINIDINE; VERAPAMIL;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CAUSE OF DEATH; DEFIBRILLATOR; HEART ELECTROPHYSIOLOGY; HIGH RISK POPULATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTATION; MAJOR CLINICAL STUDY; PACEMAKER; PROGNOSIS; SUDDEN DEATH;

AGE FACTORS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; ELECTROPHYSIOLOGY; HUMANS; RISK ASSESSMENT; SYNCOPE; TACHYCARDIA, VENTRICULAR;

EID: 0031042333     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb06206.x     Document Type: Article

References (132)

1. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: A discussion of nomenclature. Am J Cardiol 1979; 43:1242-1244.
2. Fananapazir L, Dalakas MC, Cyran F, et al. Missense mutations in the β-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1993; 90:3993-3997.
3. Cuda G, Fananapazir L, Zhu WS, et al. Skeletal muscle expression and abnormal function of β-myosin in hypertrophic cardiomyopathy. J Clin Invest 1993; 91:2861-2865.
4. Lankford EB, Epstein ND, Fananapazir L, et al. Abnormal contractile properties of muscle fibers expressing β-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 1995; 95:1409-1414.
5. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet 1996; 13:63-69.
6. Savage DD, Castelli WP, Abbott RD, et al. Hypertrophic cardiomyopathy and its markers in the general population: The great masquerader revisited: The Framingham study. J Cardiovasc Ultrasound 1983; 2:41-47.
7. Hada Y, Sakamoto T, Amano K, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. Am J Cardiol 1987; 59: 183-184.
8. Epstein ND, Lin HJ, Fananapazir L. Genetic evidence of dissociation (generational skips) of electrical from morphological forms of hypertrophic cardiomyopathy. Am J Cardiol 1990; 66:627-631.
9. Fananapazir L, Epstein ND. Prevalence of hypertrophic cardiomyopathy and limitations of screening methods. Circulation 1995; 92: 700-704.
10. Solomon SC, Jarcho JA, McKenna W, et al. Familial hypertrophic cardiomyopathy is a genetically heterogenous disease. J Clin Invest 1990; 86: 993-999.
11. Epstein ND, Fananapazir L, Lin HJ, et al. Evidence of genetic heterogeneity in five families with familial hypertrophic cardiomyopathy. Circulation 1992; 85:635-647.
12. Maron BJ, Bonow RO, Cannon RO III, et al. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology and therapy. N Engl J Med 1987; 316:780-789, 844-852.
13. Fananapazir L, McAreavey D, Epstein ND. Hypertrophic cardiomyopathy. In DP Zipes, J Jalife (eds.): Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, PA, W.B. Saunders Co., 1995, pp. 769-779.
14. Wigle ED, Rakowski H, Kimball BP, et al. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995; 92:1680-1692.
15. Glancy DL, O'Brien KP, Gold HK, et al. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. Br Heart J 1970; 32:652-659.
16. Joseph S, Balcon R, McDonald L. Syncope in hypertrophic cardiomyopathy due to asystole. Br Heart J 1972; 34:974-976.
17. Goodwin JF, Krikler DM. Arrhythmia as a cause of sudden death in hypertrophic cardiomyopathy. Lancet 1976; 2:937-940.
18. Chmielewski CA, Riley RS, Mahendran A, et al. Complete heart block as a cause of syncope in asymmetric septal hypertrophy. Am Heart J 1977; 93:91-93.
19. Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Circulation 1979; 59:866-875.
20. Canedo MI, Frank MJ, Abdulla AM. Rhythm disturbances in hypertrophic cardiomyopathy: Prevalence, relation to symptoms and management. Am J Cardiol 1980; 45:848-855.
21. Krikler DM, Daves MJ, Rowland E, et al. Sudden death in hypertrophic cardiomyopathy: Associated accessory atrioventricular pathways. Br Heart J 1980; 43:245-251.
22. McKenna WJ, Chetty S, Oakley CM, et al. Arrhythmia in hypertrophic cardiomyopathy: Exercise and 48-hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy. Am J Cardiol 1980; 45:1-5.
23. Stafford WJ, Trohman RG, Bilsker M, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 7:701-704.
24. Fananapazir L, Maron BJ. Arrhythmias in hypertrophic cardiomyopathy. In LN Horowitz (ed.): Current Management of Arrhythmias. Philadelphia, PA, BC Decker, 1990, pp. 182-194.
25. Maron BJ, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy. Circulation 1992; 85:I-57-I-63.
26. Fiddler GI, Tajik AJ, Weidman WH, et al. Idiopathic hypertrophic subaortic stenosis in the young. Am J Cardiol 1978; 42:793-799.
27. McKenna W, Deanfield J, Faruqui A, et al. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. Am J Cardiol 1981; 47: 532-538.
28. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients. Circulation 1982; 65:1388-1394.
29. McKenna WJ, Deanfield JE. Hypertrophic cardiomyopathy: An important cause of sudden death. Arch Dis Childhood 1984; 59:971-975.
30. McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11: 147-153.
31. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986; 7:204-214.
32. Fananapazir L, Epstein SE. VT and sudden death in HCM patients. Circulation 1989; 80:1923.
33. McKenna WJ, Counihan PJ, Chikamori T. Sudden death in hypertrophic cardiomyopathy: Identification and management of high risk patients. In G Baroldi, F Camerini, JF Goodwin (eds.): Advances in Cardiomyopathies. Berlin, Germany, Springer-Verlag, 1990, pp. 72-80.
34. Maron BJ, Lipson LC, Roberts WC, et al. "Malignant" hypertrophic cardiomyopathy: Identification of a subgroup of families with unusually frequent premature death. Am J Cardiol 1978; 41: 1133-1140.
35. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989; 321: 1372-1378.
36. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation. Cell 1990; 62:999-1006.
37. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992; 326: 1108-1114.
38. Rosenzweig A, Watkins H, Hwang DS, et al. Preclinical diagnosis of familial hypertrophic cardiomyopathy by genetic analysis of blood lymphocytes. N Engl J Med 1991; 325:1753-1760.
39. 403Arg-Gln mutation. Circulation 1992; 86:345-352.
40. Marian AJ, Yu QT, Mares A Jr, et al. Detection of a new mutation in the beta myosin heavy chain gene. J Clin Invest 1992; 90:2156-2165.
41. Marian AJ, Kelly D, Mares A, et al. The missense mutation in exon 13 of the beta-myosin heavy chain gene, a genetic marker for sudden cardiac death in patients with familial hypertrophic cardiomyopathy. (abstract) Circulation 1992; 86:I-16.
42. Nishi H, Kimura A, Harada H, et al. Novel missense mutation in cardiac beta myosin heavy chain gene found in a Japanese patient with hypertrophic cardiomyopathy. Biochem Biophys Res Commun 1992; 188:379-387.
43. Harada H, Kimura A, Nishi H, et al. Genetic analysis of hypertrophic cardiomyopathy. (abstract) Circulation 1992; 86:I-591.
44. Anan R, Thierfelder L, Watkins H, et al. Identification of novel myosin mutations that cause familial hypertrophic cardiomyopathy. (abstract) Circulation 1992; 86:I-229.
45. Coviello D, Spirito P, Bobola N, et al. Analysis of the prevalence of 7 cardiac: myosin heavy chain gene mutations in 13 Italian families with hypertrophic cardiomyopathy. (abstract) J Am Coll Cardiol 1993; 21:100A.
46. Al-Mahdawi S, Chamberlain S, Cleland J, et al. Identification of a mutation in the β cardiac myosin heavy chain gene in a family with hypertrophic cardiomyopathy. Br Heart J 1993; 69: 136-141.
47. Fananapazir L, Epstein ND. Genotype-phenotype correlations in hypertrophic cardiomyopathy. Circulation 1994; 89:22-32.
48. Rayment I, Holden HM, Sellers J, et al. Structural interpretation of the mutations in the β-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 1995; 92:3864-3868.
49. Thierfelder L, Watkins H, MacRae C, et al. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell 1994; 77:701-712.
50. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994; 93: 280-285.
51. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet 1995; 11: 434-437.
52. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and α-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995; 332:1058-1064.
53. MacRae C, Ghaisa N, McGarry K, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. (abstract) Circulation 1994; 90:I-25.
54. Falicov RE, Resnekov L, Bharati S. Midventricular obstruction: A variant of obstructive cardiomyopathy. Am J Cardiol 1976; 37:432-437.
55. Sekiguchi M, Hongo M, Morimoto S, et al. Long-term prognosis and treatment of hypertrophic cardiomyopathy. In M Sekiguchi, PJ Richardson (eds.): Cardiomyopathy Update 5. Prognosis and Treatment of Cardiomyopathies and Myocarditis. University of Tokyo Press, Vol. 41, p. 59.
56. Maron BJ. Evolution of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. In G Baroldi, F Camerini, JF Goodwin (eds.): Advances in Cardiomyopathies. Berlin, Germany, Springer-Verlag, 1990, pp. 7-24.
57. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. Am J Cardiol 1989; 63: 1258-1265.
58. Panza JA, Maris TJ, Maron BJ. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circulation 1992; 85: 1398-1405.
59. Fananapazir L, Epstein SE. Hemodynamic and electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. Am J Cardiol 1991; 67:280-287.
60. McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy I: Influence on prognosis. Br Heart J 1981; 46:168-172.
61. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. Am J Cardiol 1981; 48:252-257.
62. McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy: Assessment of patients at high risk. Circulation 1989; 80:1489-1492.
63. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988; 318:1255-1257.
64. Fananapazir L, Tracy CM, Leon MB, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy: A consecutive analysis in 155 patients. Circulation 1989; 80: 1259-1268.
65. Fananapazir L. Electrophysiologic studies in patients with hypertrophic cardiomyopathy: Safety and relation of results to clinical findings. In G Baroldi, F Camerini, JF Goodwin (eds.): Advances in Cardiomyopathies. Berlin, Germany, Springer-Verlag, 1990, pp. 81-89.
66. Fananapazir L, Epstein SE, Epstein ND: Investigation and clinical significance of arrhythmias in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 1991; 2:525-530.
67. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determinants in hypertrophic cardiomyopathy: Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiologic findings. Circulation 1992; 86:730-740.
68. Kramer CM, Reichek N, Ferrari VA, et al. Regional heterogeneity of function in hypertrophic cardiomyopathy. Circulation 1994; 90:186-194.
69. Spirito P, Maron BJ, Bonow RO, et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60:123-129.
70. Spirito P, Maron BJ, Chiarella F, et al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: Relation to magnitude of left ventricular hypertrophy. Circulation 1985; 72: 310-316.
71. Spirito P, Watson RM, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 1137-1142.
72. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15:1521-1526.
73. Louie EK, Maron BJ. Hypertrophic cardiomyopathy with extreme increase in left ventricular wall thickness: Functional and morphologic features and clinical significance. J Am Coll Cardiol 1986; 8:57-65.
74. McKenna WJ, Stewart JT, Nihoyannopolous P, et al. Hypertrophic cardiomyopathy without hypertrophy: Two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J 1990; 63:287-290.
75. Betocchi S, Bonow RO, Bacharach SL, et al. Isovolumic relaxation period in hypertrophic cardiomyopathy: Assessment by radionuclide angiography. J Am Coll Cardiol 1986; 7:74-81.
76. Bonow RO. Left ventricular diastolic function and myocardial ischemia in hypertrophic cardiomyopathy: Assessment by radionuclide methods. In G Baroldi, F Camerini, JF Goodwin (eds.): Advances in Cardiomyopathies. Berlin, Germany, Springer-Verlag, 1990, pp. 58-71.
77. Bonow RO. Left ventricular diastolic function in hypertrophic cardiomyopathy. Herz 1991; 16: 13-21.
78. Bonow RO, Dilsizian V, Rosing DR, et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short- and long-term effects. Circulation 1985; 72:853-864.
79. Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: Effect of verapamil. Am J Cardiol 1983; 51:1386-1391.
80. Pitcher D, Wainwright R, Maisey M, et al. Assessment of chest pain in hypertrophic cardiomyopathy using exercise thallium-201 myocardial scintigraphy. Br Heart J 1980; 44:650-656.
81. Cannon RO III, Schenke WH, Maron BJ, et al. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1987; 10:53-62.
82. O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with thallium-201 emission computed tomography. Circulation 1987; 76:1214-1223.
83. Von Dohlen TW, Prisant LM, Frank MJ. Significance of positive or negative thallium-201 scintigraphy in hypertrophic cardiomyopathy. Am J Cardiol 1989; 64:498-503.
84. Udelson JE, Bonow RO, O'Gara PT. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989; 79:1052-1060.
85. Dilsizian V, Smeltzer WR, Dextras R, et al. Regional thallium abnormalities in hypertrophic cardiomyopathy: Myocardial ischemia or disturbed cellular active cation uptake? (abstract) Circulation 1990; 82:III-9.
86. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 1979; 43:1086-1102.
87. Maron BJ, Wolfson JK, Epstein SE, et al. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 8:545-557.
88. Cannon RO III, Dilsizian V, O'Gara PT, et al. Impact of surgical relief of outflow obstruction on thallium perfusion abnormalities in hypertrophic cardiomyopathy. Circulation 1992; 85: 1039-1045.
89. Fananapazir L, Bonow RO, Dilsizian V. Dual chamber pacing relieves angina and improves myocardial perfusion abnormalities in patients with obstructive hypertrophic cardiomyopathy. (abstract) Circulation 1992; 86:I-273.
90. Fananapazir L, Barbour DJ, Winkler JB. Signal-averaged electrocardiographic identification of patients with inducible ventricular tachycardia with hypertrophic cardiomyopathy. (abstract) Circulation 1988; 78:II-51.
91. Fananapazir L, Winkler JB: Intra cardiac signal-averaged electrocardiography improves prediction of inducibility of ventricular tachycardia in hypertrophic cardiomyopathy patients. J Am Coll Cardiol 1990; 15:134A.
92. Wellens HJJ, Bär FW, Vanagt EJ. Death after ajma-line administration. Am J Cardiol 1980; 45:905.
93. Ingham RE, Mason JW, Rossen RM, et al. Electrophysiologic findings in patients with idiopathic hypertrophic subaortic stenosis. Am J Cardiol 1978; 41:811-816.
94. Anderson KP, Stinson EB, Derby GC, et al. Vulnerability of patients with obstructive hypertrophic cardiomyopathy to ventricular arrhythmia induction in the operating room. Am J Cardiol 1983; 51:811-815.
95. Kowey PR, Eisenberg R, Engel TR. Sustained arrhythmias in hypertrophic obstructive cardiomyopathy. N Engl J Med 1984; 310:1566-1569.
96. Schiavone WA, Maloney JD, Lever HM, et al. Electrophysiologic studies of patients with hypertrophic cardiomyopathy presenting with syncope of undetermined etiology. PACE 1986; 9: 476-481.
97. Watson RM, Schwartz JL, Maron BJ, et al. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death. J Am Coll Cardiol 1987; 10: 761-774.
98. McAreavey D, Dilsizian V, Panza J, et al. Favorable prognosis in 88 young hypertrophic cardiomyopathy patients during therapy based on hemodynamic, electrophysiologic and thallium scintigraphy findings, (abstract) Circulation 1993; 88:I-209.
99. Dilsizian V, Bonow RO, Epstein SE, et al. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22: 796-804.
100. Chang AC, Bartlett T, McAreavey D, et al. Atrioventricular node ablation coupled with rate responsive ventricular demand pacing improves symptoms and hemodynamics in patients with hypertrophic cardiomyopathy and drug-refractory atrial fibrillation. (abstract) Circulation 1992; 86:I-451.
101. Fananapazir L, Tripodi D, McAreavey D. Rate-responsive ventricular pacing improves drug-refractory symptoms and hemodynamic indices in non-obstructive hypertrophic cardiomyopathy following radiofrequency ablation of atrioventricular node for chronic atrial fibrillation. (abstract) Circulation 1993; 88:I-210.
102. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991; 67:169-174.
103. Fananapazir L, Epstein SE. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone. Am J Cardiol 1991; 67: 175-182.
104. Tripodi D, McAreavey D, Epstein ND, et al. Impact of the implantable defibrillator in hypertrophic cardiomyopathy patients at high risk for sudden death. J Am Coll Cardiol 1993; 21:352A.
105. O'Donoghue S, Platia E, Mispireta L, et al. Safety of defibrillator implantation in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1994;22:11A.
106. Epstein SE, Rosing DR. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981; 64:437-441.
107. Morrow AG. Hypertrophic subaortic stenosis: Operative methods utilized to relieve left ventricular outflow obstruction. J Thorac Cardiovasc Surg 1978; 76:423-430.
108. Wigle ED, Williams WG, Kimball B, et al. Rational choice of medical and/or surgical therapy in hypertrophic cardiomyopathy. In G Baroldi, F Camerini, JF Goodwin (eds.): Advances in Cardiomyopathies. Berlin, Germany, Springer-Verlag, 1990, pp. 151-167.
109. McDonald K, McWilliams E, O'Keeffe B, et al. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J 1988; 9:893-898.
110. Fananapazir L, Winkler J, Schenke B, et al. Reducing left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy by pacing-induced interventricular septal preexcitation. J Am Coll Cardiol 1989; 13:117A.
111. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 1992; 339:1318-1323.
112. Fananapazir L, Cannon RO III, Tripodi D, et al. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation 1992; 85:2149-2161.
113. McAreavey D, Fananapazir L. Altered cardiac hemodynamic and electrical state in normal sinus rhythm after chronic dual-chamber pacing for relief of left ventricular outflow obstruction in hypertrophic cardiomyopathy. Am J Cardiol 1992; 70:651-656.
114. Jeanrenaud X, Kappenberger L. The optimal patient for pacemaker treatment of hypertrophic cardiomyopathy (HOCM). (abstract) PACE 1993; 16:80.
115. McAreavey D, Fananapazir L. Ventricular pre-excitation is highly effective therapy for elderly patients with obstructive hypertrophic cardiomyopathy and symptoms refractory to medication. J Am Coll Cardiol 1993; 21:354A.
116. Sadoul N, Simon JP, Bruntz JF, et al. Long-term dual chamber pacing reduces left ventricular mass in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 21:94A.
117. McAreavey D, Tripodi D, Epstein ND, et al. Dual chamber pacing relieves outflow tract obstruction and improves symptoms in hypertrophic cardiomyopathy patients despite pre-existing left bundle branch block. J Am Coll Cardiol 1993; 21: 123A.
118. McAreavey D, Fananapazir L. DDD pacing may obviate the need for investigations of symptoms of impaired consciousness in hypertrophic cardiomyopathy. (abstract) Circulation 1994; 90:I-443.
119. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-2742.
120. Rishi F, Hulse JE, Sharma S, et al. Permanent dual chamber pacing in pediatric patients with hypertrophic obstructive cardiomyopathy. (abstract) Circulation 1994; 90:I-98.
121. Gadler F, Linde C, Dannfelt-Juhlin A, et al. Septal versus apical atrioventricular synchronous pacing in hypertrophic obstructive cardiomyopathy. PACE 1994; 17:II-16.
122. Simon JP, Sadoul N, de Chillou C, et al. Long-term dual chamber pacing improves hemodynamic function in patients with obstructive hypertrophic cardiomyopathy. PACE 1995; 18: 133A.
123. Chang AC, Atiga WL, McAreavey D, et al. Relief of left ventricular outflow tract obstruction following inadvertent left ventricular apical pacing in a patient with hypertrophic cardiomyopathy. PACE 1995; 18:1450-1454.
124. Gras D, Mabo P, de Place C, et al. Regression of mitral regurgitation with DDD pacing in obstructive hypertrophic cardiomyopathy. PACE 1995; 18:195A.
125. Gras D, Pavin D, De Place C, et al. What is the status of patients with hypertrophic obstructive cardiomyopathy treated by DDD pacing for more than 1 year? (abstract) Circulation 1995; 92:I-780.
126. Yusvinkevich SA, Khirmanov VN, Domashenko AA, et al. Treatment of HOCM by short AV delay DDD pacing. PACE 1995; 18:286A.
127. Umman S, Oncil A, Umman B, et al. Dual chamber pacemaker implantation in patients with hypertrophic obstructive cardiomyopathy. PACE 1995; 18:311A.
128. Nishimura RA, Trusty JM, Hayes DL, et al. Dual chamber pacing in patients with hypertrophic obstructive cardiomyopathy: A prospective randomized, double-blind crossover trial, (abstract) J Am Coll Cardiol 1995; 23:901-22.
129. Ghambir DS, Arora R, Khalilullah M. Dual chamber pacing in hypertrophic obstructive cardiomyopathy. PACE 1995; 18:1525A.
130. Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: A multicenter clinical experience. Heart 1996; 75:44-49.
131. Gadler F, Linde C, Juhlin-Dannfelt A, et al. Dual chamber pacing in patients with hypertrophic obstructive cardiomyopathy with and without obstruction at rest. J Am Coll Cardiol 1996; 27: 74A.
132. Pavin D, Gras D, De Place C, et al. Long-term effect of DDD pacing in patients with hypertrophic obstructive cardiomyopathy: Is there a left ventricular remodeling? (abstract) PACE 1996; 19(Pt. II):680.